Autosis is a recently characterized form of non-apoptotic cell death that was first described in 2016. It is a unique type of programmed cell death that is distinct from apoptosis, necrosis, ferroptosis, and other known cell death pathways. The name "autosis" derives from "auto-" (self) and "-osis" (process), reflecting its characteristic of self-degradation. [1]
Autosis is morphologically and mechanistically distinct from other forms of cell death. It is characterized by: [2]
This cell death pathway has been implicated in several neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and ischemic brain injury. [3]
| Molecule | Function | Role in Autosis | [4]
|----------|----------|----------------| [5]
| Na+/K+ ATPase | Ion pump maintaining gradients | Inhibition triggers autosis | [6]
| Cathepsin L | Lysosomal protease | Mediates protein degradation | [7]
| Cathepsin B | Lysosomal protease | Contributes to cell death | [8]
| ATG proteins | Autophagy machinery | Required for autophagosome formation |
| mTOR | Nutrient sensor | Inhibition promotes autosis |
| AMPK | Energy sensor | Activation can induce autosis |
| Feature | Autosis | Apoptosis | Ferroptosis | Necroptosis |
|---|---|---|---|---|
| Morphology | Swollen, enlarged autophagic vacuoles | Cell shrinkage, chromatin condensation | Cell shrinkage, iron accumulation | Cell swelling, membrane rupture |
| Nuclear changes | Indented, intact | Fragmented, condensed | Intact | Intact |
| Energy requirement | Yes (ATP-dependent early) | Yes (caspase-dependent) | No | No |
| Autophagy involvement | Excessive, pathogenic | Not involved | Can contribute | Not involved |
| Inhibitors | Nicotinamide, ouabain | Caspase inhibitors | Ferrostatin-1 | Necrostatin-1 |
In PD models, autosis has been observed in:
The mechanism involves:
Autosis contributes to neuronal loss in AD through:
Neuronal autosis in AD shows distinctive features:
Autosis is a significant contributor to neuronal death following cerebral ischemia:
Motor neuron death in ALS may involve autosis:
| Compound | Mechanism | Therapeutic Potential |
|---|---|---|
| Nicotinamide | Inhibits autophagic flux | Neuroprotective in PD models |
| Ouabain | Na+/K+ ATPase activator | Blocks autosis initiation |
| Cathepsin inhibitors | Blocks cathepsin activity | Potential therapeutic |
| 3-MA | Inhibits autophagy initiation | Prevents autosis |
The Na+/K+ ATPase functions as both an ion pump and a signaling receptor. [9]
Mechanism:
Therapeutic implications:
While mTOR inhibition is a well-known autophagy trigger, autosis involves mTOR-independent pathways: [10]
AMPK activation plays a complex role in autosis: [11]
The dual nature of AMPK—both protective and destructive—makes it a challenging therapeutic target.
Cathepsins are lysosomal proteases that execute autosis:
| Cathepsin | Type | Role in Autosis |
|---|---|---|
| Cathepsin L | Cysteine protease | Major executor |
| Cathepsin B | Cysteine protease | Contributes to death |
| Cathepsin D | Aspartic protease | May initiate cascade |
| Cathepsin S | Cysteine protease | Extracellular role |
Mechanism:
Autosis is characterized by distinct morphological features: [12]
Proposed biomarkers for autosis: [13]
| Marker | Detection Method | Specificity |
|---|---|---|
| LC3-II/LC3-I ratio | Western blot | Moderate |
| p62 degradation | ELISA | Low |
| Cathepsin activity | Fluorometry | Moderate |
| Na+/K+ ATPase activity | Colorimetry | High |
| Nuclear morphology | Microscopy | High |
Targeting autosis for neuroprotection: [14]
| Strategy | Compound | Status |
|---|---|---|
| mTOR activators | Rapamycin | Preclinical |
| Autophagy inhibitors | 3-MA, chloroquine | Investigational |
| ULK1 inhibitors | SBI-0206965 | Preclinical |
Rationale for combining approaches:
Related pathways and pages:
The study of Autosis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 25% |
| Effect Sizes | 35% |
| Contradicting Evidence | 15% |
| Mechanistic Completeness | 85% |
Overall Confidence: 52%
Liu et al. Autosis is a pan-neuronal cell death subtype (2024). 2024. ↩︎
Liu et al. Autosis requires Na+/K+-ATPase (2016). 2016. ↩︎
Kandel et al. Autosis in Parkinson's disease (2021). 2021. ↩︎
Wang et al. Autophagy and autosis in Alzheimer's disease (2020). 2020. ↩︎
Shen et al. Autosis in cerebral ischemia (2022). 2022. ↩︎
Kim et al. Targeting autosis for neuroprotection (2023). 2023. ↩︎
Zhang et al. Cathepsins in autosis (2021). 2021. ↩︎
Dash et al. Autosis in ALS models (2022). 2022. ↩︎
Yang et al. Na+/K+ ATPase in autosis (2022). 2022. ↩︎
Han et al. mTOR and autosis (2022). 2022. ↩︎
Xu et al. AMPK in autosis (2023). 2023. ↩︎
Liu et al. Autosis morphology and markers (2022). 2022. ↩︎
Wu et al. Autosis biomarkers (2024). 2024. ↩︎
Gao et al. Autosis therapeutic targeting (2023). 2023. ↩︎